Colitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:16:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Colitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease https://clinicaltrials.eu/trial/12-week-efficacy-study-of-ly4395089-and-mirikizumab-versus-mirikizumab-alone-in-adults-with-moderately-to-severely-active-crohn-s-disease/ Fri, 19 Jun 2026 04:03:41 +0000 https://clinicaltrials.eu/trial/12-week-efficacy-study-of-ly4395089-and-mirikizumab-versus-mirikizumab-alone-in-adults-with-moderately-to-severely-active-crohn-s-disease/ The trial involves adults with moderately to severely active Ulcerative Colitis or Crohn’s Disease, chronic conditions that cause inflammation of the colon or the small intestine. The study is testing a combination of an oral tablet called LY4395089 taken together with an injectable medication called mirikizumab, compared with the injectable medication alone. Mirikizumab is given as a solution for injection under the skin or into a vein.

The aim is to see whether the combination improves the lining of the intestine better than the injectable medication alone over a 12‑week period. Participants will receive the assigned medication(s) at regular intervals and will have routine visits where doctors may use a thin camera (a endoscopic exam) to look at the intestine and check for improvement. The study will last about three months, after which the results will be evaluated.

]]> Study on Infliximab and Corticosteroids for Treating Severe Colitis Caused by Immune Checkpoint Inhibitors in Patients https://clinicaltrials.eu/trial/study-on-infliximab-and-corticosteroids-for-treating-severe-colitis-caused-by-immune-checkpoint-inhibitors-in-patients/ Wed, 29 Apr 2026 14:24:25 +0000 https://clinicaltrials.eu/trial/study-on-infliximab-and-corticosteroids-for-treating-severe-colitis-caused-by-immune-checkpoint-inhibitors-in-patients/ This clinical trial is focused on studying a condition known as immune checkpoint inhibitor-related colitis, which is a type of inflammation in the colon that can occur as a side effect of certain cancer treatments. The study is investigating the effectiveness and safety of a treatment plan that includes the medication Infliximab, used alongside corticosteroids, compared to using corticosteroids alone. Infliximab is a medication that helps reduce inflammation by targeting specific proteins in the body, while corticosteroids are a type of medication that helps reduce inflammation and suppress the immune system.

The purpose of the study is to determine which treatment approach is more effective in managing severe colitis or diarrhea caused by immune checkpoint inhibitors, which are drugs used in cancer therapy to help the immune system attack cancer cells. Participants in the study will receive either the combination of infliximab and corticosteroids or corticosteroids alone. The study will monitor the participants over a period of time to assess how well the treatments work in reducing the symptoms of colitis and improving the overall health of the participants.

Throughout the study, participants will be closely observed to ensure their safety and to track any changes in their condition. The study aims to provide valuable information on the best treatment options for managing colitis related to cancer therapy, ultimately helping to improve the quality of life for patients experiencing this condition. The study is expected to continue until 2029, with the goal of gathering comprehensive data on the effectiveness and safety of the treatment options being tested.

]]>